Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis

Quarterly Journal of Nuclear Medicine

Volumn 45, Issue 1, 2001, Pages 91-99

  Serafini, A N ^a  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

Author keywords

Bone neoplasms; Bone neoplasms, secondary; Pain; Palliative care; Radiotherapy; Samarium

Indexed keywords

ANALGESIC AGENT; LEXIDRONAM SAMARIUM SM 153; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID;

ABSORPTION; BEAM THERAPY; BETA RADIATION; BINDING AFFINITY; BONE MARROW; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE CALCULATION; DOSIMETRY; DRUG APPROVAL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GAMMA RADIATION; HUMAN; METABOLIC ACTIVATION; NEOPLASM; NONHUMAN; OSTEOBLAST; PALLIATIVE THERAPY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; REVIEW; SKELETON; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANIMALS; BONE NEOPLASMS; DOGS; FEMALE; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN, INTRACTABLE; PALLIATIVE CARE; RATS; SAMARIUM;

EID: 0034960433     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. The management of intractable bone pain. A clinician's perspective
2. Bone metastases: Pathophysiology and management policy
3. Management options for painful carcinoma of the prostate
4. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease
5. Radionuclide-targeted therapy for the management of metastatic bone pain
6. An evaluation of the safety and efficacy of treatment of Sr-89 in patients who previously received wide field radiotherapy
7. A comparison of the palliative effects of Strontium-89 and external beam radiotherapy in metastatic prostate cancer
8. Results of a randomized phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
9. Skeletal localization of Samarium-153 chelates: Potential therapeutic bone agents
10. Dosimetry and toxicity by Samarium-153-EDTMP administered for bone pain due to skeletal metastases
11. Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer
12. Radiation absorbed dose calculations for Samarium-153-EDTMP localized in bone
13. Samarium 153-Sm-EDTMP biodistribution and dosimetry estimation
14. Clinical and clinicopathologic response of canine bone tumor patients to treatment with Samarium-153-EDTMP
15. Maxillectomy and targeted radionuclide therapy with S-153-EDTMP in a recurrent canine osteosarcoma
16. Pronounced therapeutic effect of Samarium-153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma tibial tumor model
17. Evaluation of Sm-153-EDTMP as a bone imaging agent during a therapeutic trial
18. Sm-153-EDTMP treatment of hormone refractory prostate carcinoma
19. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose Samarium-153 ethylenediaminetetramethylene phosphonte
20. Palliation of bone pain associated with metastatic bone cancer using Samarium-153 Lexidronam: A double-blind placebo controlled clinical trial
21. A double blinded placebo controlled study of Sm-153-EDTMP for the palliation of bone pain in patients with hormone refractory prostate carcinoma
22. A dose-controlled study of Sm-153-EDTMP in the treatment of patients with painful bone metastases
23. Efficacy and toxicity of 153Sm EDTMP in the palliative treatment of painful skeleton metastases: Results of an IAEA international multicenter study
24. Multicenter trial on the efficacy and toxicity of single dose Samarium-153 ethylenediamine methylene phosphonate as a palliative treatment for painful skeletal metastases in China
25. Multiple administration of Sm-153-Lexidronam in the treatment of painful bone metastasis
26. Retreatment of patients with metastatic bone disease with multiple doses of Samarium
27. Dose response relationship and multiple dose efficacy and toxicity of Samarium-153 Sm-153-EDTMP in metastatic cancer to bone
28. Samarium-153-EDTMP and radiosensitizing chemotherapy for treatment of disseminated skeletal metastasis
29. Quantifying the radiation dosage to individual skeletal lesions treated with Samarium-153-EDTMP
30. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate
31. In vivo tissue uptake and retention of Sn-117 m (4+) DTPA in a human subject with metastatic bone pain and in normal mice
32. Prospective 153-Sm-EDTMP therapy dosimetry by whole body scintigraphy
33. 99mTc-MDP as a surrogate quantitative imaging agent for high dose Ho-166-DOTMP
34. Sm-153-EDTMP therapy dosimetry by whole body scintigraphy
35. A new method to quantify total bone uptake of Re-186 HEDP and Sm-153 EDTMP
36. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: Total outcome following Strontium-89 therapy
37. Successful use of Samarium-153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer
38. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases
39. Samarium Sm-153-Lexidronam for the palliation of bone pain associated with metastasis
40. Local and systemic radiation for palliation of metastatic disease
41. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases
42. Half and total body irradiation for carcinoma of the prostate
43. Radiotherapy in the management of bone pain
44. Single dose half body irradiation for palliation of multiple bone metastases from solid tumors